Crinecerfont (NBI-74788)
Congenital Adrenal Hyperplasia
Key Facts
Indication
Congenital Adrenal Hyperplasia
Phase
Phase III
Status
Active (CAHtalyst)
Company
About Neurocrine Biosciences
Neurocrine Biosciences has successfully transitioned from a discovery-focused entity to a fully integrated commercial leader in neuroscience. Its mission is to relieve suffering through brave science, exemplified by the blockbuster success of INGREZZA for tardive dyskinesia and a growing portfolio in movement disorders and endocrinology. The company's strategy leverages deep neurobiological expertise to advance a diversified pipeline, pursue strategic collaborations, and expand the labels of its commercial assets to drive sustainable growth.
View full company profileTherapeutic Areas
Other Congenital Adrenal Hyperplasia Drugs
| Drug | Company | Phase |
|---|---|---|
| CRN04894 | Crinetics Pharmaceuticals | Phase 1 |